Fresenius buys out remaining 45% of biosimilars maker mAbxience
Fresenius acquired the remaining 45% stake in Madrid-based mAbxience from Insud Pharma, giving Fresenius Kabi full ownership of the biosimilars platform it first took majority control of in 2022.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.